MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$153,224K
EPS
-$0.75
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
142,631
142,287
98,924
114,249
Acquired in-process research and development
-
0
-
-
General and administrative
17,692
17,267
15,438
17,513
Total operating expenses
160,323
159,554
114,362
131,762
Interest income, net
7,095
8,056
5,333
5,604
Other income, net
4
798
-54
250
Loss before provision for income taxes
-153,224
-150,700
-109,083
-125,908
Provision for income taxes
0
-2,844
1,552
594
Net loss
-153,224
-147,856
-110,635
-126,502
Basic EPS
-0.75
-0.726
-0.61
-0.73
Diluted EPS
-0.75
-0.726
-0.61
-0.73
Basic Average Shares
205,545,373
203,654,723
181,513,386
173,643,829
Diluted Average Shares
205,545,373
203,654,723
181,513,386
173,643,829
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$153,224K
(-27.04%↓ Y/Y)
Loss before
provision for income taxes
-$153,224K
(-28.01%↓ Y/Y)
Interest income, net
$7,095K
(11.96%↑ Y/Y)
Other income, net
$4K
(-99.66%↓ Y/Y)
Total operating
expenses
$160,323K
(26.02%↑ Y/Y)
Research and development
$142,631K
(40.94%↑ Y/Y)
General and
administrative
$17,692K
(-32.02%↓ Y/Y)
Buy us a coffee
IMVT_BIG-svg
Immunovant, Inc. (IMVT)
IMVT_BIG-svg
Immunovant, Inc. (IMVT)